## AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—2015 SPCTPD/ACC/AAP/AHA TRAINING GUIDELINES FOR PEDIATRIC CARDIOLOGY FELLOWSHIP PROGRAMS – INTRODUCTION

| Committee<br>Member             | Employment  | Consultant | Speaker's<br>Bureau | Ownership/<br>Partnership/<br>Principal | Personal<br>Research       | Institutional/<br>Organizational or<br>Other Financial<br>Benefit | Expert<br>Witness |
|---------------------------------|---|------------|---------------------|---|----------------------------|---|-------------------|
| Robert D.<br>Ross (Chair)       | Children's Hospital of Michigan, Wayne State<br>University School of Medicine—Director,<br>Fellowship Programs and Director, The<br>Pulmonary Hypertension Program  | None       | None                | None                                    | None                       | None  | None              |
| Michael<br>Brook (Co-<br>Chair) | University of California-San Francisco—<br>Professor of Pediatrics, Director, Pediatric<br>Echocardiography, and Director, Pediatric<br>Cardiology Fellowship Training  | None       | None                | None                                    | None                       | None  | • Defendant, 2014 |
| Peter Koenig                    | Ann & Robert H. Lurie Children's Hospital of<br>Chicago— Director, Pediatric Cardiology<br>Fellowship; Northwestern University Feinberg<br>School of Medicine—Associate Professor of<br>Pediatrics  | None       | None                | None                                    | None                       | None  | None              |
| Jeffrey A.<br>Feinstein         | Stanford University—Professor of Pediatrics and, by courtesy, BioEngineering; Lucile Packard Children's Hospital, Stanford—Director, Pediatric Pulmonary Hypertension Service and Dunlevie Family Chair in Pulmonary Vascular Disease     | None       | None                | None                                    | None                       | • United Therapeutics*  | None              |
| Peter Lang                      | Boston Children's Hospital—Senior Associate<br>in Cardiology and Director Emeritus,<br>Fellowship Training Program in Pediatric<br>Cardiology and Cardiovascular Research;<br>Harvard Medical School—Associate Professor<br>of Pediatrics | None       | None                | None                                    | None                       | None  | None              |
| Robert Spicer                   | Children's Hospital & Medical Center,<br>Division of Pediatric Cardiology— Clinical<br>Service Chief, Cardiology  | None       | None                | None                                    | None                       | None  | None              |
| Julie A.<br>Vincent             | Columbia University, College of Physicians<br>and Surgeons—Division Chief, Pediatric<br>Cardiology, Welton M Gersony Associate<br>Professor of Pediatric Cardiology, and  | Medtronic  | None                | None                                    | • Edwards<br>Lifesciences† | • St. Jude Medical  | None              |

| Committee<br>Member | Employment  | Consultant | Speaker's<br>Bureau | Ownership/<br>Partnership/<br>Principal | Personal<br>Research | Institutional/<br>Organizational or<br>Other Financial<br>Benefit | Expert<br>Witness |
|---------------------|---|------------|---------------------|---|----------------------|---|-------------------|
|                     | Associate Professor of Pediatrics at CUMC;<br>New York-Presbyterian Hospital—Director,<br>Pediatric Interventional Cardiology |            |                     |   |                      |   |                   |

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq $10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</a> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

†No financial benefit.

 $<sup>*</sup>Significant\ relationship.\\$